Third Harmonic Bio Inc.

NASDAQ THRD

Download Data

Third Harmonic Bio Inc. Quick Ratio 2 year CAGR for the Trailing 12 Months (TTM) ending September 20, 2024

Third Harmonic Bio Inc. Quick Ratio 2 year CAGR is NA for the Trailing 12 Months (TTM) ending September 20, 2024. The quick ratio, also known as the acid-test ratio, measures a company's ability to meet its short-term obligations using its most liquid assets. It is calculated by dividing the current assets minus inventory by the current liabilities. This ratio provides insights into the company's liquidity position and its ability to pay off current liabilities without relying on inventory sales. A higher ratio suggests a stronger ability to meet short-term obligations with readily available assets. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: THRD

Third Harmonic Bio Inc.

CEO Ms. Natalie C. Holles
IPO Date Sept. 14, 2022
Location United States
Headquarters 300 Technology Square, Cambridge, MA, United States, 02139
Employees 31
Sector Healthcare
Industry Biotechnology
Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Similar companies

NXTC

NextCure  Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

EWTX

Edgewise Therapeutics Inc

NA

NA

RLYB

Rallybio Corp

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email